Did You Know...
...that Thomas Edison's patent application on his phonograph was approved by the Patent Office in just seven weeks? In contrast, it took Gordon Gould, the inventor of the laser, 30 years to obtain his patent -- finally awarded in 1988!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7834187 | Crystalline variable hydrate of (S)-6-(4-(2-((3-9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt The present invention relates to a crystalline variable hydrate of (S)-(3-pyridinecarboxamide,6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]) -hemi-succinate, a pharmaceutical formulation containing... | 11/16/2010 |
| 7501441 | Naphthyl compounds, intermediates, processes, compositions, and methods The present invention is a method for treating uterine fibroid disease using a compound of formula I wherein R1 is —H, —OH, —O(C1-C4 alkyl), —OCOC | 03/10/2009 |
| 7399867 | Selective estrogen receptor modulators containing a phenylsulfonyl group The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata. ... | 07/15/2008 |
| 7271264 | Pentacyclic oxepines and derivatives thereof, compositions and methods The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), or —OSO2(C2-C6 | 09/18/2007 |
| 7265127 | βadrenergic agonists The present invention relates to 2-imidazo[1,2-a]pyridine group containing β3 adrenergic receptor agonists or pharmaceutical salts thereof. ... | 09/04/2007 |
| 7253181 | βadrenergic agonists The present invention relates to pyrrolopyridine-3-yl group containing β3 adrenergic receptor agonists or pharmaceutical salts thereof. ... | 08/07/2007 |
| 7241772 | βadrenergic agonists The present invention relates to 2-imidazo[1,5-a]pyridine containing β3 adrenergic receptor agonists or pharmaceutical salts thereof. ... | 07/10/2007 |
| 7214697 | 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as βagonists The present invention relates to a β3 adrenergic receptor agonist of formula (I), wherein R is C3–C8 alkyl or (C3–C7 cycloalkyl)C1–C5 alk-di-yl: R1 is H, CN, halo; C1... | 05/08/2007 |
| 7205407 | 3-Substituted oxindole β3 agonists The present invention relates to a β3 adrenergic receptor agonist of Formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity ... | 04/17/2007 |
| 7122680 | 3-Substituted oxindole βagonsists The present invention relates to a β3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity. ... | 10/17/2006 |
| 7119206 | Derivative of dihydro-dibenzo (a) anthracenes and their use as selective estrogen receptor modulators The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1–C4 alkyl), —OCOC6H5, —OCO(C1–C6 alkyl), or —OSO2(C2–C6... | 10/10/2006 |
| 7105541 | Naphthyl compounds, intermediates, compositions, and methods of use The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use. ... | 09/12/2006 |
| 7087635 | 3-substituted oxindole β3 agonists The present invention relates to a β3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is usefu... | 08/08/2006 |
| 7071208 | βAdrenergic agonists The present invention relates to a β3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; useful for treating Type II diabetes and/or obesity. ... | 07/04/2006 |
| 7067510 | Dihydro-dibenzo[b,e]oxepine based selective estrogren receptor modulators, compositions and methods The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1–C4 alkyl), —OCOC6H5, —OCO(C1–C6 alkyl), or —OSO2(C2–C6... | 06/27/2006 |
| 7045628 | Synthesis of 2-aryl-1-naphthol derivatives via a tandem palladium catalyzed arylation and dehydrogenation The present invention relates to a one-pot process for preparing a compound of formula I: I; by reacting a compound of formula II with a compound of formula III: in the presence of a suitable solvent, a suitable base, a palladium catalyst and a suitable ligand. ... | 05/16/2006 |
| 7041684 | Selective βadrenergic agonists The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 receptor agonists useful in the treatment of Type II diabetes and obesity. ... | 05/09/2006 |
| 7012153 | Process for preparing benzoic acids An improved process for the preparation of 4[(2-piperidin-1-yl)ethoxy]benzoic acid derivatives, comprising reacting a haloalkyl amine of formula (III) with a compound of formula (IV) in the presence of a hydrated inorganic base in an appropriate solvent. ... | 03/14/2006 |
| 7009060 | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as βagonists The present invention relates to a β3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is u... | 03/07/2006 |
| 6962928 | Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis The current invention provides methods for inhibiting osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis comprising administering to a patient in need thereof a compound of the formula: ... | 11/08/2005 |
| 6921827 | Process for preparing 3-aryl-benzo{b} thiophenes The present invention relates to a process for preparing a compound of formula (I): which includes cyclodehydrating a compound of formula (II): in the presence of an acid activated clay or acid activated zeolite catalyst and in the presence of a suitable solvent | 07/26/2005 |
| 6911463 | 3-substituted oxindole β-3 agonists The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity. ... | 06/28/2005 |
| 6894064 | Benzothiophenes, formulations containing same, and methods This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present in... | 05/17/2005 |
| 6825220 | 3-Substituted oxindole β 3 agonists The present invention relates to a β;3 adrenergic receptor agonist of formula I: (1); or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity. ... | 11/30/2004 |
| 6797719 | Benzothiophenes, formulations containing same, and methods This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present inven... | 09/28/2004 |
| 6730792 | β3 adrenergic agonists The present invention relates to a β3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obe... | 05/04/2004 |
| 6713494 | Amorphous benzothiophenes, methods of preparation and methods of use The instant invention provides an amorphous form of a compound of formula I Methods of preparing an amorphous form of a compound of formula I, pharmaceutical formulations containing same, and methods of using same are al... | 03/30/2004 |
| 6703407 | Benzofuran compounds, compositions, and methods The present invention provides novel, reduced benzothiophenes of formula I ##STR1## wherein R is --H, --OH, --O(C1 -C4 alkyl), --O--CO--(C1 -C6 alkyl), --O--CO--Ar in which Ar is optionally substituted phenyl, or... | 03/09/2004 |
| 6653479 | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo [b] thiophene hydrochloride The present invention is directed to a novel crystalline hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo [b]thiophene hydrochloride and uses for same, including inhibition of disease states associated with estrogen dep... | 11/25/2003 |
| 6610706 | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo [b]thiophene hydrochloride The present invention is directed to a novel crystalline hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benz o[b]thiophene hydrochloride and uses for same, including inhibition of disease states associated with estrogen de... | 08/26/2003 |
| 6486179 | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy A method for treating neoplasms is disclosed, particularly using the ଲ-isozyme selective PKC inhibitor, (S)-3,4-[N, N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis-(3,3'-indo lyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC ... | 11/26/2002 |
| 6410565 | 댑-adrenergic receptor antagonists The present invention relates to an 댑 -adrenergic receptor antagonist of formula I ##STR1## or an N-oxide or pharmaceutical salt or solvate thereof; wherein A is a moiety selected from the group consisting of: ##STR2##... | 06/25/2002 |
| 6291484 | Benzothiophenes This invention provides novel benzothiophene compounds of the formula I: ##STR1## which are useful for the treatment of the various medical conditions associated with postmenopausal syndrome, as well as estrogen dependent diseases including cancer of the ... | 09/18/2001 |
| 6265581 | Selective 댣 adrenergic agonists The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective 댣 adrenergic receptor agonists useful in the treatment of Type II diabet... | 07/24/2001 |
| 6265575 | Antithrombotic diamines This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparat... | 07/24/2001 |
| 6232337 | Selective 댣 adrenergic agonists The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective 댣 receptor agonists useful in the treatment of Type II diabet... | 05/15/2001 |
| 6218425 | 8-substituted B-nor-6-Thiaequilenin compounds having activity as selective estrogen receptor modulators Certain B-nor-6-thiaequilenin compounds substituted at the 3-position with hydroxy and at the 8-position with hydroxy or alkoxy of from one to four carbon atoms are selective estrogen receptor modulators and are useful in the treatment of estrogen-related... | 04/17/2001 |
| 6147092 | Lipophilic benzothiophenes The invention provides novel benzothiophenes of the formula (I): ##STR1## wherein R1 is N-pyrrolidinyl or N-piperidinyl; R2 and R3 are independently hydrogen,--CO--(C10 -C22 alkyl), --CO--(C... | 11/14/2000 |
| 6140352 | Carbazolyl-substituted ethanolamines as selective ଲ-3 agonists Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: ##STR1## The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compou... | 10/31/2000 |
| 6133288 | Pentacyclic compounds, intermediates, processes, compositions, and methods The present invention provides compounds of formula I and II: ##STR1## wherein X is --O--, --S--, or --NR5 --; Y is --O--, --S--, --CH2 --, --CH2 CH2 --, --CH.dbd.CH--, or --NR5 --; B is --CH2 | 10/17/2000 |
